Tue. 27 Feb 2024, 4:47pm ET
Benzinga
Earnings, Earnings Beats, News
Myriad Genetics (NASDAQ:MYGN) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.01 by 300 percent. The company reported quarterly sales of $196.60 million which beat the analyst consensus estimate of $194.78 million by 0.93 percent. This is a 10.57 percent increase over sales of $177.80 million the same period last year.